These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30636741)

  • 1. Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis.
    Iulita MF; Ganesh A; Pentz R; Flores Aguilar L; Gubert P; Ducatenzeiler A; Christie S; Wilcock GK; Cuello AC
    J Alzheimers Dis; 2019; 67(1):327-341. PubMed ID: 30636741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation.
    Iulita MF; Ower A; Barone C; Pentz R; Gubert P; Romano C; Cantarella RA; Elia F; Buono S; Recupero M; Romano C; Castellano S; Bosco P; Di Nuovo S; Drago F; Caraci F; Cuello AC
    Alzheimers Dement; 2016 Nov; 12(11):1132-1148. PubMed ID: 27452424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
    Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
    Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
    Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
    Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.
    Verberk IMW; Slot RE; Verfaillie SCJ; Heijst H; Prins ND; van Berckel BNM; Scheltens P; Teunissen CE; van der Flier WM
    Ann Neurol; 2018 Nov; 84(5):648-658. PubMed ID: 30196548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study.
    Sullivan KJ; Blackshear C; Simino J; Tin A; Walker KA; Sharrett AR; Younkin S; Gottesman RF; Mielke MM; Knopman D; Windham BG; Griswold ME; Mosley TH
    Neurology; 2021 Sep; 97(11):e1123-e1131. PubMed ID: 34349010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia.
    Dukic L; Simundic AM; Martinic-Popovic I; Kackov S; Diamandis A; Begcevic I; Diamandis EP
    Clin Biochem; 2016 Feb; 49(3):213-8. PubMed ID: 26515085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of cognitive decline in Alzheimer's disease and mild cognitive impairment using the CAMCOG: a five-year follow-up.
    Conde-Sala JL; Garre-Olmo J; Vilalta-Franch J; Llinàs-Reglà J; Turró-Garriga O; Lozano-Gallego M; Hernández-Ferrándiz M; Pericot-Nierga I; López-Pousa S
    Int Psychogeriatr; 2012 Jun; 24(6):948-58. PubMed ID: 22278151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
    Mattsson-Carlgren N; Janelidze S; Palmqvist S; Cullen N; Svenningsson AL; Strandberg O; Mengel D; Walsh DM; Stomrud E; Dage JL; Hansson O
    Brain; 2020 Dec; 143(11):3234-3241. PubMed ID: 33068398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Plasma Based Biomarker of Alzheimer's Disease.
    Bradley-Whitman MA; Abner E; Lynn BC; Lovell MA
    J Alzheimers Dis; 2015; 47(3):761-71. PubMed ID: 26401710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.
    Kleinschmidt M; Schoenfeld R; Göttlich C; Bittner D; Metzner JE; Leplow B; Demuth HU
    J Alzheimers Dis; 2016; 50(1):111-26. PubMed ID: 26639953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial-derived plasma exosome proteins in Alzheimer's disease angiopathy.
    Abner EL; Elahi FM; Jicha GA; Mustapic M; Al-Janabi O; Kramer JH; Kapogiannis D; Goetzl EJ
    FASEB J; 2020 Apr; 34(4):5967-5974. PubMed ID: 32157747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.